- Lobbying
- Lobbying by Harbinger Medical Group LLC dba Tides Medical
Lobbying Relationship
Bills mentioned
H.R.2087: PELOSI Rescissions Act of 2021
Sponsor: Jeffrey Duncan (R-S.C.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Hunter Hall | Regional Director, Senate Member Office (Cassidy); Advance, Department of Commerce |
Tyron Picard | n/a |
Emily Bacque Da Silva | n/a |
Catherine Lenz | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Drug price transparency act language included in HR 2087; Consolidated Appropriations Act of 2021; additional COVID relief legislation.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate